ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

JAZZ Jazz Pharmaceuticals PLC

110.01
0.72 (0.66%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Jazz Pharmaceuticals PLC NASDAQ:JAZZ NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.72 0.66% 110.01 105.99 115.00 111.55 108.58 110.14 693,769 01:00:00

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jazz Pharmaceuticals plc - JAZZ

27/05/2016 4:41pm

PR Newswire (US)


Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Jazz Pharmaceuticals Charts.

NEW YORK, May 27, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jazz Pharmaceuticals plc ("Jazz" or the Company) (NASDAQ: JAZZ).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

[Click here to join a class action]

The investigation concerns whether Jazz and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On May 27, 2016, Bloomberg reported that Jazz had received a subpoena from the U.S. Attorney for the District of Massachusetts, initially disclosed on May 10, 2016 in the Company's 10-Q for the quarter ended March 31, 2016, seeking documents related to the Company's relationship with certain nonprofits that provide financial assistance to patients.  The Bloomberg article described how Jazz and other pharmaceutical companies make large contributions to copay charities that help patients afford their products.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: 
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-jazz-pharmaceuticals-plc--jazz-300276235.html

SOURCE Pomerantz LLP

Copyright 2016 PR Newswire

1 Year Jazz Pharmaceuticals Chart

1 Year Jazz Pharmaceuticals Chart

1 Month Jazz Pharmaceuticals Chart

1 Month Jazz Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock